Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2002 2
2004 1
2005 2
2008 2
2009 1
2010 2
2011 3
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Diagnostic biomarkers of prostate cancer.
Häggarth L, Hägglöf C, Jaraj SJ, Wester K, Pontén F, Ostman A, Egevad L. Häggarth L, et al. Scand J Urol Nephrol. 2011 Feb;45(1):60-7. doi: 10.3109/00365599.2010.526141. Epub 2010 Nov 1. Scand J Urol Nephrol. 2011. PMID: 21034352
GAD1 is a biomarker for benign and malignant prostatic tissue.
Jaraj SJ, Augsten M, Häggarth L, Wester K, Pontén F, Ostman A, Egevad L. Jaraj SJ, et al. Among authors: haggarth l. Scand J Urol Nephrol. 2011 Feb;45(1):39-45. doi: 10.3109/00365599.2010.521189. Epub 2010 Nov 22. Scand J Urol Nephrol. 2011. PMID: 21091088
Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Wahlgren T, Brandberg Y, Häggarth L, Hellström M, Nilsson S. Wahlgren T, et al. Among authors: haggarth l. Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):51-9. doi: 10.1016/j.ijrobp.2004.02.004. Int J Radiat Oncol Biol Phys. 2004. PMID: 15337539
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP. Hedlund PO, et al. Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31. Scand J Urol Nephrol. 2011. PMID: 21627403 Clinical Trial.
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group. Hedlund PO, et al. Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274. Scand J Urol Nephrol. 2008. PMID: 18432528 Clinical Trial.
14 results